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Abstract Short-chain acyl-CoA dehydrogenase deficiency
(SCADD) is an autosomal recessive inborn error of mitochon-
drial fatty acid oxidation. SCADD is biochemically character-
ized by increased C4-carnitine in plasma and ethylmalonic
acid in urine. The diagnosis of SCADD is confirmed by DNA
analysis showing SCAD gene mutations and/or variants.
SCAD gene variants are present in homozygous form in
approximately 6% of the general population and considered to
confer susceptibility to development of clinical disease.
Clinically, SCADD generally appears to present early in life
andtobemostfrequentlyassociatedwithdevelopmentaldelay,
hypotonia, epilepsy, behavioral disorders, and hypoglycemia.
However,thesesymptomsoftenameliorateandevendisappear
spontaneously during follow-up and were found to be
unrelated to the SCAD genotype. In addition, in some cases,
symptoms initially attributed to SCADD could later be
explained by other causes. Finally, SCADD relatives of
SCADD patients as well as almost all SCADD individuals
diagnosed by neonatal screening remained asymptomatic
during follow-up. This potential lack of clinical consequences
of SCADD has several implications. First, the diagnosis of
SCADD should never preclude extension of the diagnostic
workup for other potential causes of the observed symptoms.
Second, patients and parents should be clearly informed about
the potential lack of relevance of the disorder to avoid
unfounded anxiety. Furthermore, to date, SCADD is not an
optimal candidate for inclusion in newborn screening pro-
grams. Morestudies are neededto fully establish the relevance
of SCADD and solve the question as to whether SCADD is
involved in a multifactorial disease or represents a nondisease.
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Introduction
Short-chain acyl-CoA dehydrogenase (SCAD, EC 1.3.99.2)
deficiency (SCADD, OMIM 201470) is an autosomal
recessive inborn error of mitochondrial fatty acid oxidation
(FAO). SCAD catalyzes the dehydrogenation of butyryl-
CoA (C4-CoA) during the first step of the short-chain fatty
acid β-oxidation spiral. Impaired SCAD activity results in
accumulation of its substrate (C4-CoA) and the subsequent
productionofalternativemetabolites,includingthe following:
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DOI 10.1007/s10545-010-9080-z(1) the corresponding carnitine-ester, i.e., butyryl carnitine
(C4-C), (2) the corresponding glycine-ester (butyryl glycine),
(3) butyrate, and (4) ethylmalonic acid (EMA). C4-C,
measured in blood, and EMA, measured in urine, are
generally used as biochemical markers for SCADD. The
diagnosis of SCADD is usually confirmed by DNA analysis.
The majority of SCADD patients are homozygous or
compound heterozygous for two common variants of the
SCAD encoding gene (ACADS),o rf o rACADS variants in
combination with an inactivating mutation (Waisbren et al.
2008; Pedersen et al. 2008; van Maldegem et al. 2006; Tein
et al. 2008). Up to 70 different inactivating ACADS
mutations have been reported so far (Naito et al. 1990;
Gregersen et al. 2008; van Maldegem et al. 2006; Corydon et
al. 2001; Gregersen et al. 1998; Koeberl et al. 2003; Seidel et
al. 2003; Kristensen et al. 1994; Pedersen et al. 2008; Jethva
et al. 2008; Waisbren et al. 2008). There is a remarkably high
prevalence of homozygosity for ACADS variants in the
general population, with frequencies of approximately 0.3%
for the p.R171W (c.511C > T) and 5.5% for the p.G209S
(c.625G > A) variant (Maldegem et al. 2005; Nagan et al.
2003). Homozygosity for these variants is considered to
confer susceptibility to clinical disease (Corydon et al. 2001;
Gregersen et al. 1998; Gregersen et al. 2000). Most SCADD
patients have been diagnosed as a result of investigations for
neurological symptoms and/or hypoglycemia (Waisbren et
al. 2008; van Maldegem et al. 2006;T e i ne ta l .2008;
Pedersen et al. 2008). There is, however, debate on the
clinical relevance of SCADD (van Maldegem et al. 2006;
Dietzen et al. 2009). Nevertheless, newborns are screened for
SCADD in the USA [National Newborn Screening Status
Report (NNSGRC) (2008) Updated 07/07/09].
In this manuscript, we summarize the clinical aspects of
SCADD and discuss the clinical relevance of this inborn
error of metabolism.
Clinical symptoms in SCADD
Symptoms in clinically identified patients
The first SCADD patient was originally reported by Amendt
and coworkers (Amendt et al. 1987) and subsequently
genetically confirmed by Naito in 1990 (Naito et al. 1990).
The patient was reported to suffer from lethargy, hypertonia,
and circulatory problems with metabolic acidosis during her
first week of life. Although she was reported to show normal
growth and development without recurrence of metabolic
acidosis up to the age of 2 years, Bhala et al. later reported
that this patient had died, without reporting clinical details
(Bhala et al. 1995). As this publication included another
SCADD patient who died after initial presentation with
severe skeletal muscle hypotonia, a devastating clinical
course of SCADD was suggested. However, the same
publication included another two patients who initially
presented with “possible hyperactivity” and “probable
seizure activity” but with a normal follow-up. Initially, a
few other patients with SCADD had been reported (Bhala et
al. 1995;A m e n d te ta l .1987; Coates et al. 1988), however in
these patients, the diagnosis was, to our knowledge, not
genetically confirmed. As the definitive diagnosis of
SCADD requires molecular testing (van Maldegem et al.
2006), these patients are excluded from this review.
Subsequently, a large cohort of SCADD patients was
presented by Corydon et al., and several case reports were
published (Corydon et al. 2001; Baerlocher et al. 1997; Bok
et al. 2003; Birkebaek et al. 2002; Kmoch et al. 1995;
Matern et al. 2001; Kurian et al. 2004). Based on these
publications, SCADD appeared to be associated with a
wide spectrum of clinical signs and symptoms, including
developmental delay, hypotonia, epilepsy, and hypoglycemia,
and in solitary cases dysmorphic features, vomiting, failure to
thrive, hepatic dysfunction after premature delivery, and
bilateral optic atrophy. One case report suggested the
association between SCADD and acute fatty liver of
pregnancy in the mother. Again, a striking spectrum was
observed in patient outcome, which was reported for seven
patients of whom five fully recovered, one slowly progressed,
and one died (Kurian et al. 2004; Birkebaek et al. 2002;B o k
et al. 2003; Matern et al. 2001;S e i d e le ta l .2003;K m o c he t
al. 1995).
In 2006, we reported data on 31 Dutch SCADD patients
(van Maldegem et al. 2006). The most frequently reported
symptom in this cohort was developmental delay, followed by
epilepsy, behavioral disorders, and hypoglycemia. Behavioral
disorders, observed in eight out of the 31 patients, had not
been previously reported in SCADD patients. Remarkably,
most of the clinically severely affected patients belonged to
the group of patients homozygous for the c.625G > A variant.
In four patients, additional diagnoses that were highly likely
to be causing the clinical symptoms were made after the initial
diagnosis of SCADD.
In 2008, Tein and coworkers published a study on ten
SCADD patients (Tein et al. 2008) in whom developmental
delay was again the most common symptom, but this time,
hypotonia was also as frequent. In addition, this study
reported for the first time a relatively high prevalence of
lethargy (five patients), myopathy (four patients), and facial
weakness (three patients). All patients in this study were of
Ashkenazi Jewish descent, carried the c.319C > T mutation,
and were either homozygous for this mutation or had the
c.625G > A variant on the other allele. In two patients with
myopathy, a muscle biopsy revealed multiminicore disease,
a rare congenital myopathic disorder. However, other
genetic causes for multiminicore disease, in particular,
mutations in SEPN1 and RYR1, which are present in about
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the sameyear, Pedersen and coworkers published a study ona
very large cohort of 114 SCADD patients from Europe, New
Zealand, and Canada. Again developmental delay was the
most frequently reported clinical sign, in combination with
hypotonia, seizures, and failure to thrive (Pedersen et al.
2008). In addition, several patients were reported to have
failure to thrive and hypotonia without developmental delay,
and a smaller group had dysmorphic features. A third study,
also published this same year, by Waisbren and coworkers,
reportedonanothersixclinicallyidentifiedpatients(Waisbren
et al. 2008). In three of them, newborn screening failed to
detect SCADD, and in the other three, no screening for
SCADD was performed. The most significant symptoms in
these six patients were developmental delay, hypotonia,
feeding problems, failure to thrive, and epilepsy.
Age of presentation, symptom transience,
and genotype–phenotype relation in clinically
identified patients
It appears that clinical signs and symptoms in SCADD
patients generally present early in life, with almost all patients
presenting under the age of 5years (Pedersen et al. 2008; Tein
et al. 2008; van Maldegem et al. 2006; Waisbren et al. 2008).
Symptoms were transient in nine of the 31 patients in the van
Maldegem study and two of the six patients in the Waisbren
study. Furthermore, no association could be made between
genotype and clinical phenotype in the patients from the
Pedersen and the van Maldegem study.
Clinical symptoms in SCADD individuals identified
by newborn screening
WiththeimplementationofnewbornscreeningforSCADDin
the USA and Australia, the clinical spectrum of SCADD has
expanded. Several follow-up studies of SCADD newborns
diagnosed through newborn screening were published within
the last few years. The first one reported 17 SCADD newborns
who all remained symptom free at follow-up during their first
2 years of life (Rhead et al. 2002). Of the three patients
reported by Koeberl et al. (2003), one developed seizures and
a cerebral infarction at the age of 10 weeks, and the other two
remained symptom free during their first 3 years of life. One
of the eight children reported by Waisbren and co-workers
(2008) showed developmental delay consisting of a language
delay at the age of 2 years. Jethva and Ficicioglu reported a
g r o u po f1 4c h i l d r e nw i t hS C A D D ,o fw h o m1 1w e r e
identified by newborn screening and three diagnosed by
screening of sibs diagnosed through newborn screening.
During a follow-up of 1–7 years, in two of them (siblings),
speech delay was diagnosed. A causative relationship between
this speech delay and SCADD was considered unlikely, as
both parents had learning disabilities, suggesting other causes
(Jethva and Ficicioglu 2008). All four Australian SCADD
children diagnosed by newborn screening and studied during
6 years remained symptom free. SCADD has meanwhile been
excluded from the Australian screening panel because of
supposed lack of clinical significance (Wilcken 2008).
An interesting finding by Waisbren and coworkers is a
relatively high prevalence of pregnancy complications in
mothers of children diagnosed with SCADD by newborn
screening as well as in mothers of the group of SCADD
patients diagnosed because of clinical symptoms (Waisbren
et al. 2008). In five out of 14 patients, hypertension,
maternal bradycardia, pre-eclampsia, and mild hemolysis,
elevated liver enzyme levels, and a low platelet count
(HELLP syndrome) were reported. This suggests that fetal
SCADD, like other FAO disorders such as long-chain 3-
hydroxyacyl-coenzyme A dehydrogenase (LCHAD) defi-
ciency, might be associated with pregnancy complications,
as previously suggested (Matern et al. 2001). However, in
almost 30%of all pregnancies intheDutchpopulation,mildto
moderate pregnancy complications were reported, including
hypertensive disorders and pre-eclampsia (Dutch Hospital
Database 2009). Furthermore, the association between
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detected in the Dutch cohort of SCADD patients (van
Maldegem et al. 2006), as maternal disease during pregnancy
was only reported in four out of 24 patients (17%) for whom
pregnancy details were known (unpublished data).
Family studies
Thirty-seven relatives (20 parents and 17 sibs) of the
SCADD patients from the Dutch cohort were investigated
for their ACADS genotype, and nine of them were found to
have the same ACADS genotype as the proband (van
Maldegem et al. 2006) . Except for one father with an
ACADS genotype homozygous for the c.625G > A variant,
all relatives with an ACADS genotype identical to the
proband were found to have increased C4-C and/or EMA.
Eight relatives had always been healthy, whereas one had a
history of transient food refusal during her first year of life.
Clinical significance
The clinical studies discussed above show that symptoms in
SCADD generally present early in life and most frequently
concern developmental delay, hypotonia, epilepsy, behavioral
disorders, and hypoglycemia. Signs and symptoms often
ameliorate and disappear completely during follow-up. In
addition, they can sometimes be explained by other causes and
are not related to the ACADS genotype. Finally, almost all
relatives diagnosed with SCADD, as well as almost all
individuals detected by newborn screening, remain fully
asymptomatic. Based on these observations, one may question
the clinical relevance of SCADD. Indeed, we hypothesize that
the association between the reported signs and symptoms
and the diagnosis of mutations or variants in the ACADS gene
could be coincidental. As a first step to study this, we
searched the database of the laboratory for metabolic diseases
in our center for the most frequently reported symptoms of
patients for whom metabolic studies were requested between
November 2007 and November 2008. Developmental delay
wasbyfarthemostfrequentlyreported,followedbybehavioral
disorders, epilepsy, hypotonia, and hypoglycemia. The inci-
dence of these symptoms is comparable with that in the
SCADD patient group (Fig. 1), suggesting at least that there is
no specific cluster of clinical signs and symptoms in SCADD
and that the association might indeed be coincidental.
Implications with respect to policy toward SCADD
patients and families
The probable lack of clinical significance of SCADD has
important implications for the clinical management and
counselling of SCADD patients and families. First, the
diagnosis of SCADD should never preclude a full diagnostic
workupforother potentialcausesofthe symptoms.Anydelay
in doing so, might postpone the diagnosis of other potentially
treatable causes. Second, patients and parents, as well as their
physicians,shouldbeclearlyinformedaboutthepotentiallack
of clinical relevance of the detected biochemical and genetic
abnormalities concerning SCADD once the diagnosis has
beenmade.Furthermore,withouta clear clinicalphenotype of
SCADD to date, SCADD is not an optimal candidate for
inclusion in newborn screening programs. Meanwhile, further
studiesareneededtofullyunraveltheimplicationsofSCADD
in order to answer the question whether SCADD is involved
in a multifactorial disease or represents a nondisease.
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